Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
replicating RNA + LION
- Development stage
- Unknown
- Lead developer
- HDT Bio
- Modality
- Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Replicating RNA + LION is a vaccine platform developed by HDT Bio that combines self-amplifying replicon RNA (repRNA) with a Lipid InOrganic Nanoparticle (LION) delivery system. The repRNA is derived from the Venezuelan equine encephalitis virus (VEEV) TC-83 strain and encodes a replicase complex that enables intracellular amplification of the RNA, allowing for significantly lower doses compared to conventional mRNA vaccines. The LION delivery system is a stable, squalene-based oil-in-water emulsion that utilizes the cationic lipid DOTAP to electrostatically bind RNA to its surface, rather than encapsulating it. This configuration enhances stability, potentially allowing for room-temperature storage and distribution. The platform's lead candidate, HGC019 (GEMCOVAC-19), received emergency use authorization in India for COVID-19, and the technology is being explored for other infectious diseases including malaria and various viral pathogens.
- Brand names
- GEMCOVAC-19GEMCOVAC19GEMCOVAC 19GEMCOVAC-OM
- Other names
- repRNA-LIONself-amplifying RNA + LIONrepRNA + LION
02
Targets
SARS-CoV-2 spikeRdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on replicating RNA + LION.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on replicating RNA + LION.